Condition: Cystic Fibrosis · CFTR Gene Mutation · Sponsor: Arcturus Therapeutics, Inc.
ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
This description comes directly from the study's public registry record.
Clinical Trial Disclosure Manager Central Email Box · 858-900-2660 · CFclinicaltrials@arcturusrx.com
Always discuss trial participation with your own doctor first.
| University of Arizona | Tucson, Arizona, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Children's Hospital of Los Angeles | Los Angeles, California, United States | Recruiting |
| Children's National Hospital | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Joe DiMaggio Children's Hospital | Hollywood, Florida, United States | Recruiting |
| The Cystic Fibrosis Institute | Northfield, Illinois, United States | Active Not Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| UT Health San Antonio | San Antonio, Texas, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06747858